Association between class III β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: A meta-analysis
Hailong Zhang, Li Ruan, Li-Mou Zheng, David B. Whyte, Chi-Meng Tzeng, Xi-wu Zhou
Lung Cancer, 2012
Abstract
An abstract is not available for this record. Please visit the publisher website for more details.
Related Research
- A TPGS-incorporating nanoemulsion of paclitaxel circumvents drug resistance in breast cancer 2014
- Pharmacologic Sensitivity of Paclitaxel to Its Delivery Vehicles Drives Distinct Clinical Outcomes of Paclitaxel Formulations 2015
- Pharmacokinetics of paclitaxel in a hemodialysis patient with advanced gastric cancer： A case report 2006
- Synthesis and biological activity of A-nor-paclitaxel analogues 1997
- Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients 2006
References
- Introduction to Meta‐Analysis 2021
- Prediction of response to docetaxel by quantitative analysis of class I and III beta-tubulin isotype mRNA expression in human breast cancers. 2003
- Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. 2005
- No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin 2005
- [Relationship between Expression of beta-tubulin-III Plus Stathmin in Advanced Non-Small Cell Lung Cancer and its Sensitivity to Venorelbine Chemotherapy.]. 2009